Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Survivin-directed RNA interference-compositions and methods

Inactive Publication Date: 2006-12-07
ALTURA RACHEL +2
View PDF23 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0021] The instant invention is also directed to methods for diagnosing cancers and tumors that may be treated with the compositions of the instant invention. Specifically, according to the teachings of the instant invention, cancers and tumors that express survivin can be treated with the compositions of the instant invention. The diagnostic methods of the instant invention are based on performing quantitative polymerase chain reaction (PCR) analysis of RNA from a patient's tumor or cancer tissue and control healthy tissue using oligonucleotides selected from a group consisting of oligonucleotides with SEQ ID NOs. 13, 14, 15, 16, 17, 18, 19, 20 and 21 as primers to measure the level of expression of survivin; comparing the levels of expression in the cancer sample with the healthy control; and concluding that if the cancer sample expresses survivin, then the cancer can be treated with si-RNAs or sh-RNAs of the instant invention. The diagnostic method may also be performed with oligonucleotides at least 60% identical to oligonucleotides with SEQ ID NOs. 13, 14, 15, 16, 17, 18, 19, 20 and 21.
[0022] The instant invention is also directed to prognostic methods that aid in determining whether a patient's cancer may be resistant to chemotherapy and irradiation. According to the teachings of the instant invention, patients whose tumors express survivin are patients with a poor survival prognosis in part because such tumors are typically resistant to standard treatment methods such as chemotherapy and irradiation. The prognostic methods of the instant invention are based on performing a quantitative polymerase chain reaction analysis of RNA from the patient's tumor or cancer tissue and cont

Problems solved by technology

However, about 50% of cancers do not respond well to treatments with currently available chemotherapeutic compounds or radiation.
The failure to respond usually results from inability of the chemotherapeutic compounds to trigger apoptosis in the cancer cells.
Treatment with survivin inhibitors result in an aberrant localization of Aurora B kinase during assembly of the anaphase-promoting complex (Chen et al., 2003; Honda et al., 2003).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Survivin-directed RNA interference-compositions and methods
  • Survivin-directed RNA interference-compositions and methods
  • Survivin-directed RNA interference-compositions and methods

Examples

Experimental program
Comparison scheme
Effect test

example 1

Analysis of Survivin Protein Expression in Pediatric Rhabdomyosarcoma Tissue Samples

[0066] Expression of survivin-protein was evaluated in 63 primary human RMS tumors that included 31 embryonal rhabdomyosarcoma (ERMS) and 32 alveolar rhabdomyosarcoma (ARMS) tumors by immunohistochemical staining with a polyclonal antibody against survivin (FL-142, Santa Cruz).

[0067] Over 80% of the tumors analyzed for survivin protein expression (54 / 63 tumors) had a mean survivin staining score greater than or equal to 3, indicating that at least 10 to 50% of tumor cells expressed survivin

example 2

Analysis of Survivin RNA Expression in Rhabdomyosarcoma Cell Lines

[0068] Survivin RNA expression was examined in four representative RMS cell lines by quantitative PCR. Three cell lines were alveolar in origin (CW9019, RH28 and RH30) and one was embryonal (RD2).

[0069] Total RNA was isolated from 106 cells for each cell line using the Trizol® method (Invitrogen). cDNA was obtained in a random priming reaction using Omniscript reverse transcriptase (Qiagen). Primers to detect human survivin message and splice variants were designed according to the Applied Biosystem's Primer Express™ software, to quantify relative cDNA expression levels (Survivin: Forward 5′ GTG AAT TTT TGA AAC TGG ACA GAG AAA (Seq ID NO: 13); Reverse 5′ CAC TTT CTT CGC AGT TTC CTC AA (Seq ID NO: 14); Probe 5′ FAM AGC CAA GAA CAA AAT TGC AAA GGA AAC CA (Seq ID NO: 15); Survivin-2B: Forward 5′ GCA CGG TGG CTT ACG CCT G (Seq ID NO: 16); Reverse 5′ ACC GGA CGA ATG CTT TTT ATG TTC C (Seq ID NO: 17); Probe 5′ FAM ATA CCA...

example 3

Methods of Monitoring Survivin Inhibition

[0071] A cocktail of 3 DNA plasmids encoding survivin-specific shRNAs comprising SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO 3, that targeted different regions of the human survivin gene was used to eliminate survivin m-RNA in target cells (FIG. 2). The following oligonucleotides encoding the shRNAs were designed using software provided by OligoEngine company. Oligonucleotides 4 and 5 were used for the sh-RNA comprising SEQ ID NO: 1, oligonucleotides 6 and 7 were used for the sh-RNA comprising SEQ ID NO: 2 and oligonucleotides 8 and 9 were used for the sh-RNA comprising SEQ ID NO: 3. Each oligonucleotide pair was annealed, phosphorylated and cloned into Bgl II and Hind III restriction sited of pSUPER vector from OligoEngine company.

[0072] For transient transfections, plasmid DNA was transfected into proliferating CW9019 or RH30 cells using effectene transfection reagent (Qiagen) at a ratio of 1:30 (DNA:Effectene). The reporter plasmid pHcRed (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

The present invention is directed to compositions and methods for inhibiting the expression of survivin in cells expressing survivin. The invention is also directed to methods of treating conditions associated with elevated survivin, such as hyperproliferative disorders. More particularly, the invention is directed to inhibition of survivin expression using short interfering RNAs (si-RNAs) or through administration of DNA sequences yielding the expression of short hairpin RNAs (sh-RNAs).

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] The present application claims the benefit of U.S. Provisional Application No. 60 / 672,417, filed Apr. 18, 2005, which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION [0002] The present invention is directed to the field of oncology and other disease-states, such as rheumatoid arthritis, pulmonary hypertension and atherosclerosis and more specifically it provides compositions and methods for treating these diseases. More particularly, the present invention is directed to compositions and methods for promoting apoptosis in diseased cells. The invention is also directed to compositions and methods for inhibiting the anti-apoptotic activity of Survivin, and therefore, may be used for stimulating apoptosis in human tissues and cell populations that express Survivin. BACKGROUND OF THE INVENTION 1. Expression of Survivin by Patient's Cancer Cells Correlates with Poor Survival Prognosis for the Patient. [0003] Apopto...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61K31/337C12Q1/68C07H21/02
CPCC12N15/1135C12N2310/111C12N2310/14G01N2800/52C12Q2600/106C12Q2600/16G01N33/574C12Q1/6886
Inventor ALTURA, RACHELCALDAS, HUGOHOLLOWAY, MICHAEL
Owner ALTURA RACHEL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com